Skip to main content
Erschienen in: The Patient - Patient-Centered Outcomes Research 6/2016

01.12.2016 | Original Research Article

A Cross-Sectional Study of the Impact of Spasticity on Daily Activities in Multiple Sclerosis

verfasst von: Francois Bethoux, Ruth Ann Marrie

Erschienen in: The Patient - Patient-Centered Outcomes Research | Ausgabe 6/2016

Einloggen, um Zugang zu erhalten

Abstract

Background

Spasticity is frequently reported by patients with multiple sclerosis (MS). A previously published survey of participants in the North American Research Committee on Multiple Sclerosis (NARCOMS) registry showed that higher levels of spasticity were associated with higher MS-related disability and lower quality of life, but did not investigate the impact of spasticity on daily activities, and only partially assessed spasticity management.

Methods

A new cross-sectional survey was distributed to 15,679 eligible NARCOMS participants. We inquired about the degree of bother from symptoms associated with spasticity, interference with a variety of daily activities, as well as past and current treatments for spasticity.

Results

Among the 10,353 responders (66 % response rate), over 80 % reported experiencing spasticity, and more than 35 % were moderately or greatly bothered by stiffness, spasms, or pain, predominantly in the lower extremities. More severe spasticity was associated with worse disability, mobility, bladder function, and fatigue. Spasticity was most frequently reported to interfere with stair climbing, walking, and sleep. Most individuals reported receiving treatment for spasticity (mainly oral medications, stretching, home exercise, and physical therapy), yet fewer than half reported being satisfied with their current treatment.

Conclusion

Spasticity was reported by a large majority of patients with MS, and found to interfere with many daily activities. At the same time, patients were often dissatisfied with the effects of treatments for spasticity. Prospective studies are needed to better characterize the impact of spasticity in individuals with MS, and to optimize treatment strategies.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Bethoux F, Sutliff M. Management of spasticity. In: Cohen JA, Rudick RA, editors. Multiple Sclerosis Therapeutics. Fourth Edition. New York: Cambridge University Press; 2011. p. 668–677. Bethoux F, Sutliff M. Management of spasticity. In: Cohen JA, Rudick RA, editors. Multiple Sclerosis Therapeutics. Fourth Edition. New York: Cambridge University Press; 2011. p. 668–677.
2.
Zurück zum Zitat Barnes MP, Kent RM, Semlyen JK, et al. Spasticity in multiple sclerosis. Neurorehabil Neural Repair. 2003;17:66–70.CrossRefPubMed Barnes MP, Kent RM, Semlyen JK, et al. Spasticity in multiple sclerosis. Neurorehabil Neural Repair. 2003;17:66–70.CrossRefPubMed
3.
Zurück zum Zitat Haselkorn JK, Balsdon Richer C, Fry Welch D, et al. Multiple Sclerosis Council for Clinical Practice Guidelines. Overview of spasticity management in multiple sclerosis. Evidence-based management strategies for spasticity treatment in multiple sclerosis. J Spinal Cord Med. 2005;28(2):167–99.CrossRefPubMed Haselkorn JK, Balsdon Richer C, Fry Welch D, et al. Multiple Sclerosis Council for Clinical Practice Guidelines. Overview of spasticity management in multiple sclerosis. Evidence-based management strategies for spasticity treatment in multiple sclerosis. J Spinal Cord Med. 2005;28(2):167–99.CrossRefPubMed
4.
Zurück zum Zitat Gold R, Oreja-Guevara C. Advances in the management of multiple sclerosis spasticity: multiple sclerosis spasticity guidelines. Expert Rev Neurother. 2013;13(12 Suppl):55–9.CrossRefPubMed Gold R, Oreja-Guevara C. Advances in the management of multiple sclerosis spasticity: multiple sclerosis spasticity guidelines. Expert Rev Neurother. 2013;13(12 Suppl):55–9.CrossRefPubMed
5.
Zurück zum Zitat Rizzo MA, Hadjimichael OC, Preiningerova J, et al. Prevalence and treatment of spasticity reported by multiple sclerosis patients. Mult Scler. 2004;10:589–95.CrossRefPubMed Rizzo MA, Hadjimichael OC, Preiningerova J, et al. Prevalence and treatment of spasticity reported by multiple sclerosis patients. Mult Scler. 2004;10:589–95.CrossRefPubMed
6.
7.
Zurück zum Zitat Hohol MJ, Orav EJ, Weiner HL. Disease Steps in multiple sclerosis: a longitudinal study comparing disease steps and EDSS to evaluate disease progression. Mult Scler. 1999;5:349–54.CrossRefPubMed Hohol MJ, Orav EJ, Weiner HL. Disease Steps in multiple sclerosis: a longitudinal study comparing disease steps and EDSS to evaluate disease progression. Mult Scler. 1999;5:349–54.CrossRefPubMed
8.
Zurück zum Zitat Learmonth YC, Motl RW, Sandroff BM, et al. Validation of patient determined disease steps (PDDS) scale scores in persons with multiple sclerosis. BMC Neurol. 2013;13:37.CrossRefPubMedPubMedCentral Learmonth YC, Motl RW, Sandroff BM, et al. Validation of patient determined disease steps (PDDS) scale scores in persons with multiple sclerosis. BMC Neurol. 2013;13:37.CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Schwartz CE, Vollmer T, Lee H. Reliability and validity of two self-report measures of impairment and disability for MS. North American Research Consortium on Multiple Sclerosis Outcomes Study Group. Neurology. 1999;52(1):63–70.CrossRefPubMed Schwartz CE, Vollmer T, Lee H. Reliability and validity of two self-report measures of impairment and disability for MS. North American Research Consortium on Multiple Sclerosis Outcomes Study Group. Neurology. 1999;52(1):63–70.CrossRefPubMed
10.
Zurück zum Zitat Marrie RA, Goldman MD. Validity of Performance Scales for disability assessment in multiple sclerosis. Mult Scler. 2007;13:1176–82.CrossRefPubMed Marrie RA, Goldman MD. Validity of Performance Scales for disability assessment in multiple sclerosis. Mult Scler. 2007;13:1176–82.CrossRefPubMed
11.
Zurück zum Zitat World Health Organization. International Classification of Functioning, Disability and Health. Geneva; 2001. World Health Organization. International Classification of Functioning, Disability and Health. Geneva; 2001.
12.
Zurück zum Zitat Kleinbaum D, Klein M. Logistic regression. A self-learning text. 2nd ed. New York: Springer-Verlag Inc.; 2002. Kleinbaum D, Klein M. Logistic regression. A self-learning text. 2nd ed. New York: Springer-Verlag Inc.; 2002.
13.
Zurück zum Zitat Collins JG. Prevalence of selected chronic conditions, United States, 1986–88. National Center for Health Statistics. Vital Health Stat. 1993;10:1–87. Collins JG. Prevalence of selected chronic conditions, United States, 1986–88. National Center for Health Statistics. Vital Health Stat. 1993;10:1–87.
14.
Zurück zum Zitat Jacobs LD, Wende KE, Brownscheidle CM, et al. A profile of multiple sclerosis: the New York State multiple sclerosis consortium. Mult Scler. 1999;5:369–76.CrossRefPubMed Jacobs LD, Wende KE, Brownscheidle CM, et al. A profile of multiple sclerosis: the New York State multiple sclerosis consortium. Mult Scler. 1999;5:369–76.CrossRefPubMed
15.
Zurück zum Zitat Hughes C, Howard IM. Spasticity management in multiple sclerosis. Phys Med Rehabil Clin N Am. 2013;24(4):593–604.CrossRefPubMed Hughes C, Howard IM. Spasticity management in multiple sclerosis. Phys Med Rehabil Clin N Am. 2013;24(4):593–604.CrossRefPubMed
16.
Zurück zum Zitat Novotna A, Mares J, Ratcliffe S, et al. A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex(®)), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. Eur J Neurol. 2011;18(9):1122–31.CrossRefPubMed Novotna A, Mares J, Ratcliffe S, et al. A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex(®)), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. Eur J Neurol. 2011;18(9):1122–31.CrossRefPubMed
17.
Zurück zum Zitat Bensmail D, Marquer A, Roche N, et al. Pilot study assessing the impact of intrathecal baclofen administration mode on sleep-related respiratory parameters. Arch Phys Med Rehabil. 2012;93(1):96–9.CrossRefPubMed Bensmail D, Marquer A, Roche N, et al. Pilot study assessing the impact of intrathecal baclofen administration mode on sleep-related respiratory parameters. Arch Phys Med Rehabil. 2012;93(1):96–9.CrossRefPubMed
18.
Zurück zum Zitat Merlino G, Fratticci L, Lenchig C, et al. Prevalence of ‘poor sleep’ among patients with multiple sclerosis: an independent predictor of mental and physical status. Sleep Med. 2009;10(1):26–34.CrossRefPubMed Merlino G, Fratticci L, Lenchig C, et al. Prevalence of ‘poor sleep’ among patients with multiple sclerosis: an independent predictor of mental and physical status. Sleep Med. 2009;10(1):26–34.CrossRefPubMed
19.
Zurück zum Zitat Sosnoff JJ, Gappmaier E, Frame A, et al. Influence of spasticity on mobility and balance in persons with multiple sclerosis. J Neurol Phys Ther. 2011;35(3):129–32.CrossRefPubMed Sosnoff JJ, Gappmaier E, Frame A, et al. Influence of spasticity on mobility and balance in persons with multiple sclerosis. J Neurol Phys Ther. 2011;35(3):129–32.CrossRefPubMed
20.
Zurück zum Zitat Shakespeare DT, Boggild M, and Young C. Anti-spasticity agents for multiple sclerosis. Cochrane Database Syst Rev 2003;4:CD001332. Shakespeare DT, Boggild M, and Young C. Anti-spasticity agents for multiple sclerosis. Cochrane Database Syst Rev 2003;4:CD001332.
21.
Zurück zum Zitat Simpson DM, Gracies JM, Graham HK, et al. Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Assessment: Botulinum neurotoxin for the treatment of spasticity (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2008;70(19):1691–8.CrossRefPubMed Simpson DM, Gracies JM, Graham HK, et al. Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Assessment: Botulinum neurotoxin for the treatment of spasticity (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2008;70(19):1691–8.CrossRefPubMed
22.
Zurück zum Zitat Sadiq SA, Wang GC. Long-term intrathecal baclofen therapy in ambulatory patients with spasticity. J Neurol. 2006;253(5):563–9.CrossRefPubMed Sadiq SA, Wang GC. Long-term intrathecal baclofen therapy in ambulatory patients with spasticity. J Neurol. 2006;253(5):563–9.CrossRefPubMed
23.
Zurück zum Zitat Zahavi A, Geertzen JH, Middel B, et al. Long term effect (more than five years) of intrathecal baclofen on impairment, disability, and quality of life in patients with severe spasticity of spinal origin. J Neurol Neurosurg Psychiatry. 2004;75(11):1553–7.CrossRefPubMedPubMedCentral Zahavi A, Geertzen JH, Middel B, et al. Long term effect (more than five years) of intrathecal baclofen on impairment, disability, and quality of life in patients with severe spasticity of spinal origin. J Neurol Neurosurg Psychiatry. 2004;75(11):1553–7.CrossRefPubMedPubMedCentral
24.
Zurück zum Zitat Poulos C, Kinter E, Yang JC, Bridges JF, Posner J, Reder AT. Patient preferences for injectable treatments for multiple sclerosis in the United States: a discrete-choice experiment. Patient. 2016;9(2):171–80.CrossRefPubMed Poulos C, Kinter E, Yang JC, Bridges JF, Posner J, Reder AT. Patient preferences for injectable treatments for multiple sclerosis in the United States: a discrete-choice experiment. Patient. 2016;9(2):171–80.CrossRefPubMed
25.
Zurück zum Zitat Collongues N, Vermersch P. Multiple sclerosis spasticity: ‘state-of-the-art’ questionnaire survey of specialized healthcare professionals. Expert Rev Neurother. 2013;13(3 Suppl 1):21–5.CrossRefPubMed Collongues N, Vermersch P. Multiple sclerosis spasticity: ‘state-of-the-art’ questionnaire survey of specialized healthcare professionals. Expert Rev Neurother. 2013;13(3 Suppl 1):21–5.CrossRefPubMed
26.
Zurück zum Zitat Minden SL, Hoaglin DC, Hadden L, et al. Access to and utilization of neurologists by people with multiple sclerosis. Neurology. 2008;70:1141–9.CrossRefPubMed Minden SL, Hoaglin DC, Hadden L, et al. Access to and utilization of neurologists by people with multiple sclerosis. Neurology. 2008;70:1141–9.CrossRefPubMed
27.
Zurück zum Zitat Bray M, Wolfson C, Moore F, et al. General practitioner preferences in managing care of multiple sclerosis patients. Can J Neurol Sci 2016;43(1):142–8.CrossRefPubMed Bray M, Wolfson C, Moore F, et al. General practitioner preferences in managing care of multiple sclerosis patients. Can J Neurol Sci 2016;43(1):142–8.CrossRefPubMed
Metadaten
Titel
A Cross-Sectional Study of the Impact of Spasticity on Daily Activities in Multiple Sclerosis
verfasst von
Francois Bethoux
Ruth Ann Marrie
Publikationsdatum
01.12.2016
Verlag
Springer International Publishing
Erschienen in
The Patient - Patient-Centered Outcomes Research / Ausgabe 6/2016
Print ISSN: 1178-1653
Elektronische ISSN: 1178-1661
DOI
https://doi.org/10.1007/s40271-016-0173-0

Weitere Artikel der Ausgabe 6/2016

The Patient - Patient-Centered Outcomes Research 6/2016 Zur Ausgabe

Acknowledgement to Referees

Acknowledgement to Referees